{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1391975831219083648.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2491/jjsth.31.584"}},{"identifier":{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/jjsth/31/6/31_2020_JJTH_31_6_584-590/_pdf"}},{"identifier":{"@type":"NAID","@value":"130007953938"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2021085217"}}],"dc:title":[{"@language":"en","@value":"Hemorrhagic complication during anticoagulant therapy and antidote"},{"@language":"ja","@value":"抗凝固療法中の出血と中和剤"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"ja","@value":"<p>ビタミンK拮抗経口抗凝固薬（vitamin K antagonist: VKA）や直接経口抗凝固薬（direct oral anticoagulant: DOAC）による抗凝固療法中は，頭蓋内出血や消化管出血などの出血性合併症が一定の頻度で発現する．出血時はその重症度に応じて抗凝固薬の休薬，止血処置，輸液によるバイタル安定，出血性脳卒中では十分な降圧を図るとともに，中和剤がある場合はその投与を考慮する．中和剤としてVKAに対してプロトロンビン複合体を，トロンビン阻害薬ダビガトランに対してイダルシズマブを考慮する．第Xa因子阻害薬に対する中和剤アンデキサネットアルファは本邦では治験が進められている（2020年11月現在）．抗凝固療法中の急性脳梗塞症例に対する抗凝固作用中和後のrt-PA静注療法に関して，ダビガトラン療法中は凝固亢進作用を有さないイダルシズマブ投与を考慮できるが，VKA療法中は凝固を亢進させる可能性があるプロトロンビン複合体を投与せずに血栓回収術を優先させるべきである．</p>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1411975831219083648","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000411017993"}],"foaf:name":[{"@language":"en","@value":"YASAKA Masahiro"},{"@language":"ja","@value":"矢坂 正弘"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"国立病院機構九州医療センター脳血管・神経内科"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09157441"},{"@type":"LISSN","@value":"09157441"},{"@type":"EISSN","@value":"18808808"}],"prism:publicationName":[{"@language":"en","@value":"Japanese Journal of Thrombosis and Hemostasis"},{"@language":"ja","@value":"日本血栓止血学会誌"},{"@language":"en","@value":"Nihon Kessen Shiketsu Gakkaishi"},{"@language":"en","@value":"Jpn J Thromb Hemost"},{"@language":"ja","@value":"血栓止血誌"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society on Thrombosis and Hemostasis"},{"@language":"ja","@value":"一般社団法人 日本血栓止血学会"}],"prism:publicationDate":"2020","prism:volume":"31","prism:number":"6","prism:startingPage":"584","prism:endingPage":"590"},"reviewed":"false","url":[{"@id":"https://www.jstage.jst.go.jp/article/jjsth/31/6/31_2020_JJTH_31_6_584-590/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2021085217"}],"availableAt":"2020","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Bleeding","dc:title":"Bleeding"},{"@id":"https://cir.nii.ac.jp/all?q=Anticoagulation","dc:title":"Anticoagulation"},{"@id":"https://cir.nii.ac.jp/all?q=Vitamin%20K%20antagonist","dc:title":"Vitamin K antagonist"},{"@id":"https://cir.nii.ac.jp/all?q=Direct%20oral%20anticoagulant","dc:title":"Direct oral anticoagulant"},{"@id":"https://cir.nii.ac.jp/all?q=Antidote","dc:title":"Antidote"},{"@id":"https://cir.nii.ac.jp/all?q=Bleeding","dc:title":"Bleeding"},{"@id":"https://cir.nii.ac.jp/all?q=Anticoagulation","dc:title":"Anticoagulation"},{"@id":"https://cir.nii.ac.jp/all?q=Vitamin%20K%20antagonist","dc:title":"Vitamin K antagonist"},{"@id":"https://cir.nii.ac.jp/all?q=Direct%20oral%20anticoagulant","dc:title":"Direct oral anticoagulant"},{"@id":"https://cir.nii.ac.jp/all?q=Antidote","dc:title":"Antidote"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011143777462528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146138867840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620277021056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A specific antidote for dabigatran: functional and structural characterization"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621543859072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Idarucizumab for Dabigatran Reversal — Full Cohort Analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166989599104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Apixaban versus Warfarin in Patients with Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094571403904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095470281472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Enlargement of Spontaneous Intracerebral Hemorrhage"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661332551680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gastrointestinal Bleeding in Acute Ischemic Stroke: Recent Trends from the Fukuoka Stroke Registry"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043504738816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044937264512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519310208896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993469543808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470715131904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Intensity of Anticoagulation and Clinical Outcomes in Acute Cardioembolic Stroke"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893255750656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894516927872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370109094528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370409710592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846074695552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320535397504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793825133568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rates and Implications for Hospitalization of Patients ≥65 Years of Age With Atrial Fibrillation/Flutter"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270310449408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270701843200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270820884096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271226292864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Anticoagulation on Infarct Size and Clinical Outcome in Acute Cardioembolic Stroke"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679615881728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Xa 阻害薬による抗凝固療法中に視床出血を発症し，第IX 因子複合体製剤投与後も血腫増大を呈した1 症例"},{"@language":"en","@value":"A case of thalamic hemorrhage which occurred during anticoagulant therapy with Xa inhibitor and expanded even after the administration of prothrombin complex concentrate"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680248488704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"CLINICAL USE OF CRYOPRECIPITATE OR FIBRINOGEN CONCENTRATE TO PREVENT MASSIVE HEMORRHAGE DURING SURGERY"},{"@language":"ja","@value":"術中大量出血を防ぐための新たな輸血治療―クリオプレシピテートおよびフィブリノゲン濃縮製剤投与効果の検討―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282752350259968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Corresponding to Geriatric Traumatic Brain Injury in Patients taking Antithrombotic Agent"},{"@language":"ja","@value":"高齢者頭部外傷への対応におけるピットフォール"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238077665152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"脳神経外傷学の過去・現在……そして未来"},{"@language":"en","@value":"Neurotrauma in Japan, Past, Present, and Future"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2008186412"},{"@type":"CROSSREF","@value":"10.2491/jjsth.31.584"},{"@type":"CIA","@value":"130007953938"}]}